Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Regulatory Peptides

• Publication date

  2004-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.REGPEP.2003.11.003PMID 14759561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002cited by this paper
• No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP‐1 and intravenous glucose

  2001cited by this paper
• Intensive insulin therapy in critically ill patients.

  2001cited by this paper
• Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

  1999cited by this paper
• Management of hyperglycemia in hospitalized patients receiving parenteral nutrition.

  1997cited by this paper
• Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

  1997cited by this paper
• Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

  1996cited by this paper
• Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

  1996cited by this paper
• Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.

  1996cited by this paper
• Aging exaggerates the blood glucose response to total parenteral nutrition.

  1996cited by this paper
• Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

  1995cited by this paper
• Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

  1994cited by this paper
• Is GLP-1 amide an endogenous antagonist at GLP-1 receptors?

  1994cited by this paper
• Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

  1993cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Gut hormones and diabetes mellitus.

  1992cited by this paper
• Management of glucose abnormalities in patients receiving total parenteral nutrition.

  1989cited by this paper
• Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans.

  1988cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin

  1983cited by this paper
• Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

  1982cited by this paper
• The incretin concept today

  1979cited by this paper
• Entero-insular axis.

  1969cited by this paper

• Targeting Metabolic Dysfunction in Parkinson’s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection

  2025cites this paper
• GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

  2025cites this paper
• The Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?

  2024cites this paper
• Meta‐analysis on GLP‐1 mediated modulation of autophagy in islet β‐cells: Prospectus for improved wound healing in type 2 diabetes

  2024cites this paper
• Recent Progress in Nutrition

  2021cites this paper
• The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential

  2019cites this paper
• Transition from intravenous insulin to subcutaneous long-acting insulin in critical care patients on enteral or parenteral nutrition.

  2017cites this paper
• Nutrition and Hyperglycemia Management in the Inpatient Setting (Meals on Demand, Parenteral, or Enteral Nutrition)

  2017cites this paper
• EFFECTS OF GINSENG AND ITS FOUR PURIFED GINSENOSIDES (Rb2, Re, Rg1, Rd) ON HUMAN PANCREATIC ISLET β CELL IN VITRO.

  2016cites this paper
• Glucagon orchestrates stress‐induced hyperglycaemia

  2016cites this paper
• Drug Information Rounds

  2015cites this paper
• The potential role of incretin therapy in the hospital setting

  2015cites this paper
• The Use of Non-Insulin Anti-Diabetic Agents to Improve Glycemia Without Hypoglycemia in the Hospital Setting: Focus on Incretins

  2014cites this paper
• Glucose Metabolism in Critically Ill Patients

  2013cites this paper
• Glucose metabolism in the critically ill.

  2012cites this paper
• Exogenous Glucagon-Like Peptide-1 for Hyperglycemia in Critically Ill Patients

  2012cites this paper
• Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes

  2011influential citation
• The potential role of glucagon‐like peptide‐1 or its analogues in enhancing glycaemic control in critically ill adult patients

  2011cites this paper
• Effect of Urtica dioica leaf extract on activities of nucleoside diphosphate kinase and acetyl coenzyme, a carboxylase, in normal and hyperglycemic rats

  2011cites this paper
• Diabesity: an overview of a rising epidemic.

  2011cites this paper
• Bench-to-bedside review: The gut as an endocrine organ in the critically ill

  2010cites this paper
• The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill

  2010cites this paper
• Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*

  2010cites this paper
• Acute Responses of Gastrointestinal Hormones to Both Oral and Parenteral Intradialytic Nutrition

  2010cites this paper
• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  2010cites this paper
• Diabesity: therapeutic options

  2010cites this paper
• Waking up the gut in critically ill patients

  2010cites this paper
• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

  2009cites this paper
• Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge

  2009cites this paper
• Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

  2009cites this paper
• incretin-based therapies: new treatments for type 2 diabetes in the new millennium

  2009cites this paper
• Ginseng on Hyperglycemia: Effects and Mechanisms

  2008cites this paper
• The Role of Nitric Oxide Synthase in Post-Operative Hyperglycaemia

  2008cites this paper
• The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)

  2007cites this paper
• American ginseng modulates pancreatic beta cell activities

  2007cites this paper
• Maintaining A Physiological Blood Glucose Level with ‘Glucolevel’, A Combination of Four Anti-Diabetes Plants Used in the Traditional Arab Herbal Medicine

  2007cites this paper
• Hyperglycemia in Acute Ischemic Stroke: A Vascular Perspective

  2007cites this paper
• Nutrition Support and Hyperglycemia

  2006cites this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cites this paper
• A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and Glucagon-Like Peptide-1 Analog

  2006cites this paper
• American Ginseng Stimulates Insulin Production and Prevents Apoptosis through Regulation of Uncoupling Protein-2 in Cultured β Cells

  2006cites this paper
• A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and GLP-1 Analog

  2005cites this paper
• Acute Hyperglycemia Induced by Ketamine/Xylazine Anesthesia in Rats: Mechanisms and Implications for Preclinical Models

  2005cites this paper
• Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

  2005cites this paper
• Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes

  2005cites this paper
• Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

  2004cites this paper